Merus N.V.

📍 Utrecht, Netherlands👥 274 employees💰 Last funded Sep 2017
Biotechnology Research🌐 merus.nl
Website LinkedIn
Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl Read our Community Guidelines: https://merus.nl/community-guidelines/
4
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
2
Investor activity2005–2017 · investors recorded per year
20051201012015120171
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Merus N.V.?
Merus N.V. has 4 investors on record on gritt.io.
When did Merus N.V. last raise funding?
The most recent investment in Merus N.V. recorded on gritt.io was in September 2017.
What industry is Merus N.V. in?
Merus N.V. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Merus N.V. based?
Merus N.V. is headquartered in Utrecht, Netherlands.